Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.

In August 2025, Dren Bio announced a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics ...

--Citius Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has approved LYMPHIR™, a novel immunotherapy for the treatment of r/r cutaneous T-cell lymphoma after ...

A greater proportion of patients with cutaneous T-cell lymphoma and sepsis were older, Black and experienced more sepsis episodes compared with patients with sepsis and a different type of non ...

In terms of numbers, CTCL affects around 31,000 people in the U.S. and approximately 38,000 people in Europe. For patients, the high unmet need represents a significant burden.

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks PR Newswire PRINCETON, N.J., April 14, 2025 ...

Considered a rare but manageable disease, cutaneous T-cell lymphoma (CTCL) is a type of non-Hodgkin lymphoma that affects about 6 per 1 million individuals. Unlike many other cancer types, CTCL is a ...

Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice. Journal of Clinical Investigation, 2020; DOI: 10.1172/JCI135711 ...

BioWorld Content on 'CTCL'Soligenix Inc. is scratching its chin as it decides how to react to the U.S. FDA’s refusal to file letter regarding Hybryte (synthetic hypericin) for treating early stage ...

Xiaofei Song et al. Genomic and single-cell landscape reveals novel drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma. Cancer Discovery, 2022 DOI: 10.1158/2159-8290 ...

Participation requires: Cutaneous T cell lymphoma patients with a confirmed or suspected diagnosis of mycosis fungoides or Sezary syndrome Adult patients (18+) Pediatric patients (age 6-17) ...